Altered expression of Pax-5 gene in human myeloma cells

被引:42
作者
Mahmoud, MS [1 ]
Huang, NH [1 ]
Nobuyoshi, M [1 ]
Lisukov, IA [1 ]
Tanaka, H [1 ]
Kawano, MM [1 ]
机构
[1] HIROSHIMA UNIV, RES INST RADIAT BIOL & MED,DEPT HEMATOL & ONCOL, MYELOMA STUDY GRP,MINAMI KU, HIROSHIMA 734, JAPAN
关键词
D O I
10.1182/blood.V87.10.4311.bloodjournal87104311
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent phenotypic analysis of plasma cells showed that normal plasma cells do express the B-cell lineage-specific molecule CD19, but their malignant counterpart (myeloma cells) are CD19(-). To clarify the meaning of loss of CD19 antigen on myeloma cells, we first compared the expression of CD19 and Pax-5 genes among B cells, normal plasma cells, myeloma cell lines, and primary myeloma cells, because the Pax-5 gene was reported to encode the transcriptional factor, B-cell-specific activating protein (BSAP), necessary for CD19 gene expression. Neither CD19 nor Pax-5 mRNA could be detected in those primary myeloma cells and cell lines, whereas normal plasma cells did express both CD19 and Pax-5 mRNA. Furthermore, we could confirm that BSAP-binding activity was not detected in the nuclear extract from CD19(-) myeloma cell line (KMS-5) but was detected in CD19(+) B-cell line (Raji) by gel-shift assay. We further examined the expression of E2A and Id genes, because E2A and Id are considered to be positive and negative regulators in the expression of Pax-5 gene, respectively. However, no significant differences in the expression of these E2A and Id-2 genes could be observed between myeloma cells and normal plasma cells. Therefore, these data suggest that the altered expression of Pax-5, but not E2A or Id, is responsible for the loss of CD19 expression in human myeloma cells, although the underlying mechanism of the altered Pax-5 gene expression remains to be clarified. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:4311 / 4315
页数:5
相关论文
共 20 条
[1]   E2A PROTEINS ARE REQUIRED FOR PROPER B-CELL DEVELOPMENT AND INITIATION OF IMMUNOGLOBULIN GENE REARRANGEMENTS [J].
BAIN, G ;
MAANDAG, ECR ;
IZON, DJ ;
AMSEN, D ;
KRUISBEEK, AM ;
WEINTRAUB, BC ;
KROP, I ;
SCHLISSEL, MS ;
FEENEY, AJ ;
VANROON, M ;
VANDERVALK, M ;
TERIELE, HPJ ;
BERNS, A ;
MURRE, C .
CELL, 1994, 79 (05) :885-892
[2]   THE PROTEIN ID - A NEGATIVE REGULATOR OF HELIX-LOOP-HELIX DNA-BINDING PROTEINS [J].
BENEZRA, R ;
DAVIS, RL ;
LOCKSHON, D ;
TURNER, DL ;
WEINTRAUB, H .
CELL, 1990, 61 (01) :49-59
[3]   IN MULTIPLE-MYELOMA, CLONOTYPIC B-LYMPHOCYTES ARE DETECTABLE AMONG CD19(+) PERIPHERAL-BLOOD CELLS EXPRESSING CD38, CD56, AND MONOTYPIC IG LIGHT-CHAIN [J].
BERGSAGEL, PL ;
SMITH, AM ;
SZCZEPEK, A ;
MANT, MJ ;
BELCH, AR ;
PILARSKI, LM .
BLOOD, 1995, 85 (02) :436-447
[4]  
BRADBURY LE, 1992, J IMMUNOL, V149, P2841
[5]  
BRADBURY LE, 1993, J IMMUNOL, V151, P2915
[6]  
CALLARD RE, 1992, J IMMUNOL, V148, P2983
[7]  
DILOSA RM, 1991, J IMMUNOL, V146, P4071
[8]   PAX IN DEVELOPMENT [J].
GRUSS, P ;
WALTHER, C .
CELL, 1992, 69 (05) :719-722
[9]  
HARADA H, 1993, BLOOD, V81, P2658
[10]   EXPRESSION OF CD21 ANTIGEN ON MYELOMA CELLS AND ITS INVOLVEMENT IN THEIR ADHESION TO BONE-MARROW STROMAL CELLS [J].
HUANG, NH ;
KAWANO, MM ;
MAHMOUD, MS ;
MIHARA, K ;
TSUJIMOTO, T ;
NIWA, O ;
KURAMOTO, A .
BLOOD, 1995, 85 (12) :3704-3712